Supporting data for "Preclinical Evaluation of Macrophage-Targeted Therapies in Esophageal Squamous Cell Carcinoma Using PatientDerived Organoid Xenograft Models"

All the data from my PhD were uploaded here including a readme file, which includes a full description on the Description on the project:Esophageal squamous cell carcinoma (ESCC) carries a poor prognosis and is frequently complicated by cancer cachexia. Suitable pre-clinical models that capture both tumor biology and systemic wasting are limited.Overall, the study delivers a comprehensive pre-clinical framework, spanning PDOX model development, cachexia modelling, and macrophage-targeted therapy, that (i) faithfully recapitulates ESCC and its cachexia, (ii) demonstrates that CSF1R blockade or PPAR-γ activation mitigates wasting, (iii) shows that DAC augments myeloid depletion and, in combination with PLX3397, achieves synergistic tumor control, and (iv) defines functional TAM subsets as therapeutic targets. These findings support dual TAM-targeted strategies to simultaneously alleviate cachexia and improve tumor control in ESCC.

本数据集收录了本人博士阶段的全部研究数据，同时附带一份说明文档（readme file），其中完整介绍了本项目的相关内容：食管鳞状细胞癌（Esophageal squamous cell carcinoma, ESCC）预后较差，且常并发癌症恶病质。目前能够同时模拟肿瘤生物学特性与全身性消耗状态的合格临床前模型较为匮乏。本研究构建了一套完整的临床前研究框架，涵盖患者来源异种移植模型（PDOX）构建、恶病质建模以及巨噬细胞靶向治疗三大模块，其核心发现包括：(i) 精准复现食管鳞状细胞癌及其恶病质表型；(ii) 证实集落刺激因子1受体（CSF1R）阻断或过氧化物酶体增殖物激活受体γ（PPAR-γ）激活可缓解全身性消耗症状；(iii) 发现DAC可增强髓系细胞耗竭效果，且与PLX3397联合使用时可产生协同抗肿瘤效应；(iv) 明确了具有功能活性的肿瘤相关巨噬细胞（Tumor-associated macrophages, TAM）亚群可作为治疗靶点。上述研究结果支持采用双重巨噬细胞靶向策略，以同时缓解食管鳞状细胞癌患者的恶病质症状并提升肿瘤控制效果。